E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Influence of Blockade at Specific Levels of the Coagulation Cascade on Restenosis in a Rabbit Atherosclerotic Femoral Artery Injury Model
Yangsoo Jang,Luis A. Guzman,A. Michael Lincoff,Michael Gottsauner-Wolf,Farhard Forudi,Charles E. Hart,David W Courtman,Mirella Ezban,Stephen G. Ellis,Eric J. Topol +9 more
TL;DR: Treatment with DEGR-VIIa or TFPI for 3 days in this rabbit atherosclerotic injury model reduced angiographic restenosis and decreased neointimal hyperplasia compared with controls, highlighting the importance of early initiators of the extrinsic coagulation pathway, especially factor VII and tissue factor, in the response to arterial injury.
Journal ArticleDOI
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.
Howard C. Herrmann,David J. Moliterno,E. Magnus Ohman,Amanda Stebbins,Christopher Bode,Amadeo Betriu,Florian Forycki,Jerry S Miklin,William Bachinsky,A. Michael Lincoff,Robert M. Califf,Eric J. Topol +11 more
TL;DR: Early PCI facilitated by a combination of abciximab and reduced-dose reteplase was safe and effective and has several advantages for acute MI patients, which should be confirmed in a dedicated, randomized trial.
Journal ArticleDOI
Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization
A. Michael Lincoff,Robert M. Califf,Keaven M. Anderson,Harlan F. Weisman,Frank V. Aguirre,Neal S. Kleiman,Robert A. Harrington,Eric J. Topol +7 more
TL;DR: The syndrome of unstable angina identifies patients who will experience particularly marked reductions in the risk of death and MI with abciximab during coronary intervention as well as other patients in the EPIC trial without unstableAngina.
Journal ArticleDOI
Local Intraluminal Infusion of Biodegradable Polymeric Nanoparticles A Novel Approach for Prolonged Drug Delivery After Balloon Angioplasty
Luis A. Guzman,Vinod Labhasetwar,Cunxian Song,Yangsoo Jang,A. Michael Lincoff,Robert J. Levy,Eric J. Topol +6 more
TL;DR: Local administration of nanoparticles with incorporated dexamethasone significantly decreased neointimal formation and appears to have important potential for clinical applications in local drug delivery.